BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/20/2023 4:48:38 PM | Browse: 504 | Download: 1473
Publication Name World Journal of Clinical Cases
Manuscript ID 86183
Country China
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Case Report
Article Title Triplet regimen as a novel modality for advanced unresectable hepatocellular carcinoma: A case report and review of literature
Manuscript Source Unsolicited Manuscript
All Author List Ying Zhao, Guo-Sheng He and Gong Li
ORCID
Author(s) ORCID Number
Gong Li http://orcid.org/0000-0002-6437-7785
Funding Agency and Grant Number
Corresponding Author Gong Li, MD, Doctor, Doctor, Researcher, Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No. 168 Litang Road, Changping District, Beijing 102218, China. dr_gongli@163.com
Key Words Hepatocellular carcinoma; Portal vein tumor thrombosis; Radiotherapy; Combination therapy; RACIB; Case report
Core Tip Primary hepatoma patients with inferior vena cava tumor thrombus and portal vein tumor thrombus are rare, and both are inferior prognostic factors for such patients. There are no worldwide consensuses or guidelines on the diagnosis and treatment of hepatocellular carcinoma patients with macrovascular invasion. We used a new treatment model for this patient: radiotherapy combined with target therapy followed by immune maintenance therapy; and achieved extended survival.
Publish Date 2023-09-20 16:48
Citation Zhao Y, He GS, Li G. Triplet regimen as a novel modality for advanced unresectable hepatocellular carcinoma: A case report and review of literature. World J Clin Cases 2023; 11(27): 6558-6564
URL https://www.wjgnet.com/2307-8960/full/v11/i27/6558.htm
DOI https://dx.doi.org/10.12998/wjcc.v11.i27.6558
Full Article (PDF) WJCC-11-6558-with-cover.pdf
Full Article (Word) WJCC-11-6558.docx